Literature DB >> 20480234

Kinetics and intrapulmonary disposition of tilmicosin after single and repeated oral bolus administrations to rabbits.

G Gallina1, L Lucatello, I Drigo, M Cocchi, S Scandurra, F Agnoletti, C Montesissa.   

Abstract

Tilmicosin (TIM, Pulmotil) was administered to eight rabbits by oral gavage at a dose of 12.5 mg/kg body weight for 2, 5, and 7 days, and its plasma kinetics and intrapulmonary disposition were investigated. TIM concentrations in plasma samples collected after days 1 and 6 of treatment were measured by high-performance liquid chromatography with ultraviolet detection. The pharmacokinetic parameters, obtained by non-compartmental analysis of TIM plasma concentrations, did not show any significant variations between days 1 and 6. From the second day of treatment, TIM concentrations attained in lung tissue and pulmonary alveolar macrophages (PAM) exceeded those in plasma by 7- and 400-fold, respectively, and high levels were maintained in lung tissues during the entire treatment duration. After the first day of withdrawal, a fast decline in TIM levels in both plasma and lung tissue was observed, but in PAM, much higher concentrations were maintained after 3 days of TIM withdrawal.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20480234     DOI: 10.1007/s11259-010-9385-2

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  7 in total

Review 1.  The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics.

Authors:  P L Toutain; J R E del Castillo; A Bousquet-Mélou
Journal:  Res Vet Sci       Date:  2002-10       Impact factor: 2.534

Review 2.  Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.

Authors:  Q A McKellar; S F Sanchez Bruni; D G Jones
Journal:  J Vet Pharmacol Ther       Date:  2004-12       Impact factor: 1.786

Review 3.  Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy.

Authors:  D Honeybourne
Journal:  Curr Opin Pulm Med       Date:  1997-03       Impact factor: 3.155

4.  Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes.

Authors:  B Scorneaux; T R Shryock
Journal:  J Vet Pharmacol Ther       Date:  1998-08       Impact factor: 1.786

5.  Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

Authors:  Andreas H Groll; Caron A Lyman; Vidmantas Petraitis; Ruta Petraitiene; Derek Armstrong; Diana Mickiene; Raul M Alfaro; Robert L Schaufele; Tin Sein; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

6.  Pulmonary disposition of tilmicosin in foals and in vitro activity against Rhodococcus equi and other common equine bacterial pathogens.

Authors:  A Womble; S Giguère; Y V S N Murthy; C Cox; E Obare
Journal:  J Vet Pharmacol Ther       Date:  2006-12       Impact factor: 1.786

7.  Anti-inflammatory benefits of tilmicosin in calves with Pasteurella haemolytica-infected lungs.

Authors:  A C Chin; D W Morck; J K Merrill; H Ceri; M E Olson; R R Read; P Dick; A G Buret
Journal:  Am J Vet Res       Date:  1998-06       Impact factor: 1.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.